MA58208B1 - Acides nucléiques pour inhiber l'expression de lpa dans une cellule - Google Patents

Acides nucléiques pour inhiber l'expression de lpa dans une cellule

Info

Publication number
MA58208B1
MA58208B1 MA58208A MA58208A MA58208B1 MA 58208 B1 MA58208 B1 MA 58208B1 MA 58208 A MA58208 A MA 58208A MA 58208 A MA58208 A MA 58208A MA 58208 B1 MA58208 B1 MA 58208B1
Authority
MA
Morocco
Prior art keywords
expression
lpa
inhibiting
cell
nucleic acids
Prior art date
Application number
MA58208A
Other languages
English (en)
Inventor
Lucas Bethge
Judith Hauptmann
Christian Frauendorf
David Anthony Rider
Adrien Weingaertner
Sibylle Dames
Steffen Schubert
Stephan Tenbaum
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/081106 external-priority patent/WO2019092283A1/fr
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of MA58208B1 publication Critical patent/MA58208B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des produits et des compositions ainsi que leurs utilisations. En particulier, l'invention concerne des produits d'acide nucléique qui interfèrent avec l'expression du gène lpa ou inhibent son expression, de préférence pour une utilisation en tant que traitement, prévention ou réduction du risque de souffrir d'une maladie cardiovasculaire telle qu'une coronaropathie, une sténose aortique ou un accident vasculaire cérébral, ou tout autre trouble, pathologie ou syndrome lié à des taux élevés de particules de lp(a).
MA58208A 2018-11-13 2019-11-13 Acides nucléiques pour inhiber l'expression de lpa dans une cellule MA58208B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2018/081106 WO2019092283A1 (fr) 2017-11-13 2018-11-13 Acides nucléiques permettant d'inhiber l'expression de lpa dans une cellule
EP19174466 2019-05-14
PCT/EP2019/081158 WO2020099476A1 (fr) 2018-11-13 2019-11-13 Acides nucléiques permettant d'inhiber l'expression de lpa dans une cellule

Publications (1)

Publication Number Publication Date
MA58208B1 true MA58208B1 (fr) 2022-12-30

Family

ID=66554180

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58208A MA58208B1 (fr) 2018-11-13 2019-11-13 Acides nucléiques pour inhiber l'expression de lpa dans une cellule

Country Status (31)

Country Link
US (3) US20220002722A1 (fr)
EP (2) EP3880818B1 (fr)
JP (1) JP7245328B2 (fr)
KR (1) KR102553386B1 (fr)
CN (2) CN119842706A (fr)
AU (1) AU2019380628B2 (fr)
BR (1) BR112021009213A2 (fr)
CA (1) CA3119239C (fr)
CL (1) CL2021001225A1 (fr)
CO (1) CO2021007372A2 (fr)
CR (1) CR20210301A (fr)
DK (1) DK3880818T3 (fr)
EA (1) EA202190895A1 (fr)
ES (1) ES2932295T3 (fr)
FI (1) FI3880818T3 (fr)
HR (1) HRP20221358T1 (fr)
HU (1) HUE060703T2 (fr)
IL (1) IL283159B1 (fr)
LT (1) LT3880818T (fr)
MA (1) MA58208B1 (fr)
MX (1) MX2021005590A (fr)
PE (1) PE20211282A1 (fr)
PH (1) PH12021550801B1 (fr)
PL (1) PL3880818T3 (fr)
PT (1) PT3880818T (fr)
RS (1) RS63778B1 (fr)
SA (1) SA521421963B1 (fr)
SG (1) SG11202103882QA (fr)
SI (1) SI3880818T1 (fr)
SM (1) SMT202300050T1 (fr)
WO (1) WO2020099476A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3607069T3 (da) * 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger
HRP20230127T1 (hr) 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
PH12021550801B1 (en) 2018-11-13 2024-04-26 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
WO2022079221A1 (fr) 2020-10-16 2022-04-21 Sanofi Compositions d'arn et méthodes d'inhibition de lipoprotéine (a)
WO2023041508A2 (fr) * 2021-09-14 2023-03-23 Argonaute RNA Limited Traitement d'une maladie cardiovasculaire
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
KR20240147992A (ko) 2022-02-09 2024-10-10 사일런스 테라퓨틱스 게엠베하 Lpa 발현의 치료적 억제
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024013334A1 (fr) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Acides nucléiques pour inhiber l'expression de l'agt dans une cellule
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024151937A1 (fr) * 2023-01-13 2024-07-18 Eli Lilly And Company Compositions pharmaceutiques contenant des oligonucléotides thérapeutiques et schémas posologiques les utilisant
CN119585432B (zh) * 2023-08-22 2025-08-12 成都先衍生物技术有限公司 一种靶向AGT基因表达的siRNA及其缀合物和用途
WO2025064821A2 (fr) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Composés et procédés d'inhibition de lpa
WO2026046153A1 (fr) * 2024-08-26 2026-03-05 倍臻生物技术（苏州）有限公司 Acide ribonucléique double brin modifié et son utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US20060160759A1 (en) 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
CN101278059A (zh) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 诊断和治疗肾细胞癌的方法
WO2009151644A2 (fr) 2008-06-13 2009-12-17 Yale University Inhibiteurs à petites molécules d'autotaxine et procédés d'utilisation
EP2490699A1 (fr) * 2009-10-20 2012-08-29 Santaris Pharma A/S Administration orale d'oligonucléotides de lna thérapeutiquement efficaces
EP3564374A1 (fr) * 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions et procédés de modulation d'acides nucléiques cibles
WO2016149020A1 (fr) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Agents d'interférence arn
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (fr) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Acide nucléique lié à un glycoconjugué trivalent
DK3607069T3 (da) 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger
HRP20230127T1 (hr) * 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
EP3735461A1 (fr) * 2017-11-13 2020-11-11 Silence Therapeutics GmbH Acides nucléiques permettant d'inhiber l'expression de l'aldh2 dans une céllule
PH12021550801B1 (en) 2018-11-13 2024-04-26 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell

Also Published As

Publication number Publication date
CN113227372A (zh) 2021-08-06
AU2019380628A1 (en) 2021-05-20
EP4219712A3 (fr) 2023-11-22
PH12021550801A1 (en) 2021-10-04
RS63778B1 (sr) 2022-12-30
HRP20221358T1 (hr) 2022-12-23
IL283159A (en) 2021-06-30
IL283159B1 (en) 2026-01-01
US20260078372A1 (en) 2026-03-19
BR112021009213A2 (pt) 2021-08-10
FI3880818T3 (fi) 2022-12-15
SI3880818T1 (sl) 2023-01-31
US20220002722A1 (en) 2022-01-06
MX2021005590A (es) 2023-01-24
SA521421963B1 (ar) 2024-03-25
SG11202103882QA (en) 2021-05-28
EP4219712A2 (fr) 2023-08-02
SMT202300050T1 (it) 2023-03-17
WO2020099476A1 (fr) 2020-05-22
US11499153B2 (en) 2022-11-15
HUE060703T2 (hu) 2023-04-28
EA202190895A1 (ru) 2021-08-10
JP2022507282A (ja) 2022-01-18
KR102553386B1 (ko) 2023-07-07
CL2021001225A1 (es) 2021-12-24
CA3119239A1 (fr) 2020-05-22
DK3880818T3 (da) 2022-12-05
AU2019380628B2 (en) 2024-10-31
US20220170016A1 (en) 2022-06-02
PT3880818T (pt) 2022-12-06
JP7245328B2 (ja) 2023-03-23
LT3880818T (lt) 2022-12-27
ES2932295T3 (es) 2023-01-17
CO2021007372A2 (es) 2021-07-09
PE20211282A1 (es) 2021-07-19
CA3119239C (fr) 2024-06-04
PH12021550801B1 (en) 2024-04-26
KR20210095878A (ko) 2021-08-03
PL3880818T3 (pl) 2023-01-23
EP3880818A1 (fr) 2021-09-22
CN119842706A (zh) 2025-04-18
CR20210301A (es) 2021-09-16
EP3880818B1 (fr) 2022-09-28

Similar Documents

Publication Publication Date Title
MA58208B1 (fr) Acides nucléiques pour inhiber l'expression de lpa dans une cellule
EP4219716A3 (fr) Acides nucléiques pour inhiber l'expression de lpa dans une cellule
MA52488B1 (fr) Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
CA3155921A1 (fr) Compositions d'agents a base d'arni ciblant la huntingtine (htt) et leurs procedes d'utilisation
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
SA521430753B1 (ar) Kcnt1 مثبطات وطرق استخدامها
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
FR3029790B1 (fr) Microbille d'hydrogel de chitosane
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA42439B1 (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA34516B1 (fr) Imidizopyridazines substituees
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA42701B1 (fr) Compositions d'insuline à action rapide
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA46611A (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
MA63885A1 (fr) Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer
EP3485892A4 (fr) Composition destinée à la prévention ou au traitement d'un déficit cognitif léger ou d'une démence comprenant de l'hydrogène en tant que principe actif
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
FR3059236B1 (fr) Extraits de plantes du genre tagetes et leurs utilisations
MA53521A1 (fr) Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications